Picture by VinothChandar via Flickr Innovative Commons.. If there’s any lesson to learn from biomedicine from the past year, it’s to anticipate the unexpected. Who have thought a year ago that the patents on the breast cancer genes BRCA1 and BRCA2, kept by Myriad Genetics, will be overturned by a US federal court? Or a federal judge would temporarily upend President Barack Obama’s executive order allowing funding for research involving human embryonic stem cells? Furthermore, 2010 noticed a shake-up for the genetic testing industry after the US Meals and Medication Administration and Authorities Accountability Office voiced worries about the direct-to-customer spit kits.Stump, M.D., Executive Vice President, Research and Development, HGS. Belimumab has met the principal endpoint in both of its pivotal Stage 3 trials. Earlier this full month, we and GSK submitted marketing applications for belimumab in the United States and Europe. We look forward to the account and conclusions of regulatory authorities now. Carlo Russo, M.D., Senior Vice President, Biopharm Advancement, GSK, said, With both of the pivotal Phase 3 trials completed effectively, the results presented at major scientific meetings and regulatory applications now under review, we quite definitely hope that we will be able to deliver a fresh option for the treating systemic lupus. Belimumab can be an investigational drug and the initial in a new class of medications called BLyS-specific inhibitors.